Stephen Brady, Tempest Therapeutics CEO
Tempest Therapeutics’ triple combo shows promise in first-line liver cancer, stock jumps
Tempest Therapeutics said Friday morning that its experimental liver cancer therapy on top of standard-of-care treatments helped shrink tumors in more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.